<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82031">
  <stage>Registered</stage>
  <submitdate>18/05/2007</submitdate>
  <approvaldate>24/05/2007</approvaldate>
  <actrnumber>ACTRN12607000278437</actrnumber>
  <trial_identification>
    <studytitle>Older People, Omega-3, and Cognitive Health</studytitle>
    <scientifictitle>An 18 month study investigating the effects of  long chain omega-3 polyunsaturated fatty acids supplementation on cognition and wellbeing in older people.</scientifictitle>
    <utrn />
    <trialacronym>EPOCH</trialacronym>
    <secondaryid>Commonwealth Scientific Industrial Research Organisation: le51</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>age-related cognitive decline in older adults</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Studies of the normal brain and nervous system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>18 month intervention of either: ACTIVE: long chain omega-3 polyunsaturated fatty acids (430mg DHA; 150 mg EPA) Participants will consume 2 capsules in the morning and 2 in the evening for 18 months.</interventions>
    <comparator>PLACEBO: Olive oil capsules
Participants will consume 2 capsules in the morning and 2 in the evening for 18 months.</comparator>
    <control>Placebo</control>
    <interventioncode>Behaviour</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Rate of cognitive decline</outcome>
      <timepoint>Participants will be assessed on a broad battery of cognitive tasks and measures of  wellbeing, at 4 six-monthly intervals.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in well being measures</outcome>
      <timepoint>Participants will be assessed on a broad battery of cognitive tasks and measures of  wellbeing, at 4 six-monthly intervals.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary outcomes are: 
plasma fatty acid changes
blood pressure, oxidative stress and inflammation.</outcome>
      <timepoint>Markers of plasma fatty acid status, oxidative stress, systemic inflammation, and blood pressure will be assessed at each of the 4 six-monthly assessment points.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> fluency in the English language  agree to not commence own n-3 fish-oil (or algal) supplementation throughout the duration of the study</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria> already taking n-3 fish-oil (or algal) supplements  inability to swallow capsules physically unable to attend laboratory/use pen and paper  diagnosed with intellectual disability, clinical depression, dementia  score &lt; 24 on the dementia screeening measure at screening, have had head injury, stroke, coronary artery bypass surgery, any known degenerative neurological disease, history of alcohol or drug abuse</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>allocation concealed when it was done by central randomisation by computer</concealment>
    <sequence>random allocation using computer software clinstat</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>longitudinal, 4 repeat testings at 6-monthly intervals. Participants, test administrators, and data anlayst will be blinded until after the main outcome data is analysed for an effect.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/08/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Commonwealth Scientific Industrial Research Organisation</primarysponsorname>
    <primarysponsoraddress>PO Box 10041, Adelaide BC, South Australia, 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Brailsford Robertson Award (Adelaide University)</fundingname>
      <fundingaddress>The University of Adelaide
Adelaide South Australia 5000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Commonwealth Scientific Industrial Research Organisation</fundingname>
      <fundingaddress>PO Box 10041, Adelaide BC, South Australia, 5000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>n/a</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study design: a parallel 18-month randomised, double-blind, placebo-controlled intervention trial with repeated measures every 6 months, totalling 4 measurement points. 
Participants: 400 men &amp; women, aged 65-90 years. 
Intervention: Half the participants will receive fish-oil capsules and the other half will receive placebo capsules for 18 months. 
Outcome measures: cognitive performance and cognitive change, well-being, blood pressure, oxidative stress, and inflammation. 
Demographic and nutritional data will be collected as covariates.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>CSIRO Human Nutrition</ethicname>
      <ethicaddress />
      <ethicapprovaldate>2/05/2007</ethicapprovaldate>
      <hrec>06/19</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Vanessa Danthiir</name>
      <address>CSIRO Human Nutrition
PO Box 10041 (Gate 13 Kintore Avenue)
Adelaide  BC SA 5000</address>
      <phone>+61 8 83050605</phone>
      <fax>+61 8 83038899</fax>
      <email>vanessa.danthiir@csiro.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Vanessa Danthiir</name>
      <address>CSIRO Human Nutrition
PO Box 10041 (Gate 13 Kintore Avenue)
Adelaide  BC SA 5000</address>
      <phone>+61 8 8305 0605</phone>
      <fax>+61 8 83038899</fax>
      <email>vanessa.danthiir@csiro.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Vanessa Danthiir</name>
      <address />
      <phone>+61 8 8305 0605</phone>
      <fax />
      <email>vanessa.danthiir@csiro.au</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>